Taylor Daly

May 31, 2024 | jdsupra.com | Reggie Babin |Craig B. Bleifer |Taylor Daly

May 31, 2024 Reggie Babin, Craig Bleifer, Taylor Daly, Caroline Kessler Akin Gump Strauss Hauer & Feld LLP + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: On May 16th, the U.S. Drug Enforcement Administration (DEA) issued a Notice of Proposed Rulemaking (NPRM) to initiate the rescheduling of marijuana from a Schedule I to a Schedule III drug.1The NPRM, which was published in the Federal Register on May 21st, is the first step of...

May 29, 2024 | akingump.com | Caroline D. Kessler |Craig B. Bleifer |Reggie Babin |Taylor Daly

On May 16th, the U.S. Drug Enforcement Administration (DEA) issued a Notice of Proposed Rulemaking (NPRM) to initiate the rescheduling of marijuana from a Schedule I to a Schedule III drug.1The NPRM, which was published in the Federal Register on May 21st, is the first step of a formal rulemaking process required by the Controlled Substances Act (CSA) for rescheduling a controlled substance. This process, as detailed below, will likely include a public hearing before any final rule is published.

Feb 26, 2024 | jdsupra.com | Reggie Babin |Craig B. Bleifer |Taylor Daly

Key Points The scientific review supporting HHS’s recommendation to DEA that cannabis be reclassified from a Schedule I to a Schedule III drug was published on January 12, 2024. Classifying cannabis as a Schedule III substance would have significant implications for state-legal cannabis businesses, including eliminating certain tax burdens for state-legal businesses and easing research restrictions.

Feb 15, 2024 | mondaq.com | Taylor Daly |Jason Daniel |Barbara Niederkofler |William K. Wetmore

Earlier today, the Securities and Exchange Commission in a 3‑2 vote adopted new Rules 3a5‑4 and 3a44‑2 (together, the Dealer Rules) under the Securities Exchange Act of 1934, as amended (the Exchange Act), that will define who is deemed to be buying and selling securities as a regular part of its business and thus considered a "dealer" or "government securities dealer."1 Section 3(a)(5) of the Exchange Act generally defines a "dealer"2 as "any person engaged in the business of buying and...

Jan 12, 2024 | akingump.com | Caroline D. Kessler |Craig B. Bleifer |Reggie Babin |Taylor Daly

By: Caroline D. Kessler, Craig B. Bleifer, Reggie Babin, Taylor DalyKey PointsThe scientific review supporting HHS’s recommendation to DEA that cannabis be reclassified from a Schedule I to a Schedule III drug was published on January 12, 2024. Classifying cannabis as a Schedule III substance would have significant implications for state-legal cannabis businesses, including eliminating certain tax burdens for state-legal businesses and easing research restrictions.